Copyright
©The Author(s) 1999.
World J Gastroenterol. Oct 15, 1999; 5(5): 375-382
Published online Oct 15, 1999. doi: 10.3748/wjg.v5.i5.375
Published online Oct 15, 1999. doi: 10.3748/wjg.v5.i5.375
Usual manifestations | Symptoms possibly related to complications of GER* |
Specific manifestations | |
Regurgitation | Symptoms related to anaemia (iron deficiency anaemia) |
Nausea | Haematemesis and melaena |
Vomiting | Dysphagia (as a symptom of oesophagitis or due to stricture formation) |
Weight loss and/or failure to thrive | |
Epigastric or retrosternal pain | |
“Non-cardiac angina-like” chest pain | |
Pyrosis or heartburn, pharyngeal burning | |
Belching, postprandial fullness | |
Irritable oesophagus | |
General irritability (infants) | |
Unusual presentations | |
GER related to chronic respiratory disease (bronchitis, asthma, laryngitis, pharyngitis, etc.) | |
Sandifer Sutcliffe syndrome | |
Rumination | |
Apnea, apparent life threatening event and sudden infant death syndrome | |
Associated to congenital and/or central nervous system abnormalities | |
Intracranial tumors, cerebral palsy, psychomotory retardation |
Contraindications to cisapride administ ration in pediatric patients |
-Combination with medication also known to prolong the QT interval or potent CYP3A4 inhibitors, such as astemizole, fluconazole, |
itraconazole, ketoconazole, miconazole, eythromycin, clarithromycin, troleandomycin, nefazodone, indinavir, ritonavir, josamycin, |
diphemanil, terfaridine. |
-Use of the above medications by a breast-feeding mother, as secretion i n mother's milk of most of these drugs is unknown. |
-Known hypersensitivity to cisapride. |
-Known congenital long QT syndrome or known idiopathic QT prolongation. |
Precautions for cisapride administration in pediatric patients |
-Prematurity (a starting dose of 0.1 mg/kg, 4 times daily may be used, although 0.2 mg/kg is also for prematures the normal dose) |
-Hepatic or renal failure (particularly when on chronic dialysis). In these cases, it is recommended to start with 50% of the |
recommended dose. |
-Uncorrected electrolyte disturbances (hypokalemia, hypomagnesemia, hypocal cemia), as may occur in prematures, |
in severe diarrhea, in treatment with potassium-wasting diuretics such as furosemide or acetazolamide. |
-History of significant cardiac disease including serious ventricular arrhythmia, second or third degree antrioventricular block, congestive heart failure or ischaemic |
heart disease, QT prolongation associated with diabetes mellitus. |
-History of sudden infant death in a sibling, and/or history of a “serious ” apparent life threatening event in the infant or a sibling. |
-Intracranial abnormalities, such as encephalitis or haemorrhage, grape fruit juice. |
- Citation: Yvan V. Diagnosis and treatment of gastroesophageal reflux disease in infants and children. World J Gastroenterol 1999; 5(5): 375-382
- URL: https://www.wjgnet.com/1007-9327/full/v5/i5/375.htm
- DOI: https://dx.doi.org/10.3748/wjg.v5.i5.375